Pfizer Inc. (PFE)
Activist Investor Starboard Value Take $1 Billion Stake in Pfizer
Activist investor Starboard Value is seeking to spur a turnaround of Pfizer, taking a stake of about $1 billion in the struggling pharmaceuticals giant, according to a person familiar with the matter. Charlie Wells reports on Bloomberg Television.
Pfizer Has an Activist. Pharma Giant Is Latest Target of Starboard.
Activist investor Starboard Value has reportedly amassed a $1 billion stake in Pfizer.
Starboard Value's $1 billion move: will Pfizer see a much-needed revival?
In a bid to reshape Pfizer's future, activist investor Starboard Value has acquired a stake worth approximately $1 billion, according to reports. The move comes as the pharmaceutical giant faces mounting challenges, including declining demand for its Covid-19 products and increased competition.
Pfizer: Activist investor Starboard Value takes $1bn stake
Activist investor Starboard Value has acquired a $1 billion stake in Pfizer Inc (NYSE:PFE, ETR:PFE) and is pushing for changes at the pharmaceutical giant, according to the Wall Street Journal. While Starboard's specific plans remain unclear, it has reportedly engaged with former Pfizer executives Ian Read and Frank D'Amelio to support its efforts.
Starboard reportedly takes $1 billion stake in Pfizer, seeks changes
Activist investor Starboard Value has taken a $1 billion stake in beleaguered drugmaker Pfizer Inc. and is seeking a turnaround, the Wall Street Journal reported late Sunday.
Activist investor Starboard has just informed Pfizer it has taken a significant stake
Starboard Value has taken a significant stake in Pfizer, said people familiar with the matter. The drug giant's stock has dropped significantly since its 2021 COVID-19 vaccine rollout.
Activist Starboard Value has $1 billion Pfizer stake, taps former executives for help, sources say
Starboard Value has amassed a roughly $1 billion stake in drugmaker Pfizer, according to people familiar with the matter. The activist fund run by Jeff Smith is looking to tap former Pfizer CEO Ian Read and ex-finance chief Frank D'Amelio, although it is unclear in what capacity.
Activist Starboard Value Takes $1 Billion Stake in Pfizer
The drugmaker's shares have slumped as demand for Covid-19 vaccines and treatments has slowed.
Pfizer: Patent Fears Priced In
Pfizer's stock has delivered a 5% total return since early July, outperforming the broader U.S. market, reinforcing my bullish stance. The latest quarterly earnings showed YoY revenue growth, marking the first growth since FQ4 2022. My dividend discount model suggests that Pfizer's stock is extremely undervalued.
Is Pfizer a Buy Right Now or a Value Trap?
Pfizer has prepared for today's challenges
Pfizer (PFE) Stock Declines While Market Improves: Some Information for Investors
In the closing of the recent trading day, Pfizer (PFE) stood at $28.61, denoting a -0.21% change from the preceding trading day.
Billionaire Ken Griffin Loaded Up on This High-Yield Dividend Stock. Should You?
A 5.8% forward-dividend yield is just one reason the hedge fund manager likes this stock.
